Neuberger Berman Group
APGE icon

Neuberger Berman Group’s Apogee Therapeutics APGE Stock Holding History

Neuberger Berman Group’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-99,648
Closed -$7.52M – 2167
2025
Q4 		$7.52M Buy
+99,648
New +$6.28M 0.01% 873

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Neuberger Berman Group's APGE Position: Q1 2026 in Review

Neuberger Berman Group sold out of Apogee Therapeutics (APGE) in Q1 2026, closing a stake of 99,648 shares — an estimated $7.52M sold.

Neuberger Berman Group first reported a position in APGE in Q4 2025 and held it in 1 quarter. The position peaked at $7.52M in Q4 2025. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Neuberger Berman Group reported no remaining Apogee Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Neuberger Berman Group sold 99,648 Apogee Therapeutics shares in Q1 2026, an estimated $7.52M.
  • Neuberger Berman Group first reported a position in Apogee Therapeutics in Q4 2025 and held it in 1 quarter.
  • Neuberger Berman Group's Apogee Therapeutics position peaked at $7.52M in Q4 2025.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.